Chemical Xenogenization of Experimental Tumors

Overview

Journal Cancer Metastasis Rev

Specialty Oncology

Date 1987 Jan 1

PMID 3297373

Citations 10

Authors

P Puccetti

L Romani

M C Fioretti

Affiliations

Soon will be listed here.

Abstract

Chemical xenogenization occurs when experimental tumors, treated in vivo or in vitro with selected chemicals, become immunogenic, i.e., able to induce a strong rejection response, immunological in nature, in the histocompatible hosts. Unlike modifications induced by haptens, changes in tumor cell immunogenicity associated with chemical xenogenization are heritable as a result of drug interference with the genetic code. Drugs endowed with potent mutagenic activity are known to be powerful xenogenizing agents, and their mechanism of action is traditionally regarded as involving changes in DNA nucleotide sequence. Triazene and nitrosoguanidine derivatives are among the best known examples of this type of compound, and a large body of information has been accumulated over the years regarding the immunogenic properties of the tumor variants obtained following treatment with those xenogenizing agents. The present paper reviews this information, and also discusses the therapeutic implications of xenogenization in experimental systems of tumor immunotherapy. Xenogenization of murine tumors has also been obtained by means of chemicals devoid of mutagenic activity but capable of affecting gene transcriptional activity. The characteristics of this 'new' type of xenogenization are also reviewed and compared to those of triazene xenogenization.

Citing Articles

Abscopal Effect and Drug-Induced Xenogenization: A Strategic Alliance in Cancer Treatment?.

Franzese O, Torino F, Giannetti E, Cioccoloni G, Aquino A, Faraoni I Int J Mol Sci. 2021; 22(19).

PMID: 34639014 PMC: 8509363. DOI: 10.3390/ijms221910672.

Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.

Franzese O, Torino F, Fuggetta M, Aquino A, Roselli M, Bonmassar E Oncotarget. 2017; 8(25):41641-41669.

PMID: 28404974 PMC: 5522228. DOI: 10.18632/oncotarget.16335.

Immunotherapy of malignancy by in vivo gene transfer into tumors.

Plautz G, Yang Z, Wu B, Gao X, Huang L, Nabel G Proc Natl Acad Sci U S A. 1993; 90(10):4645-9.

PMID: 8506311 PMC: 46569. DOI: 10.1073/pnas.90.10.4645.

Effects of prolonged treatment with decarbazine on tumor metastatic potential in mice bearing Lewis lung carcinoma.

Zorzet S, Perissin L, Rapozzi V, Pacor S, Giraldi T Clin Exp Metastasis. 1995; 13(2):97-104.

PMID: 7882619 DOI: 10.1007/BF00133614.

Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens.

Romani L, Grohmann U, Fazioli F, Puccetti P, Mage M, Fioretti M Cancer Immunol Immunother. 1988; 26(1):48-54.

PMID: 3257903 PMC: 11038002. DOI: 10.1007/BF00199847.

References

Altevogt P . Effects of mutagens on the immunogenicity of tumor cells: comparison of cell surface changes induced by 5-azacytidine and N-methyl-N'-nitro-N-nitrosoguanidine. Cancer Res. 1986; 46(6):2912-6. View

Klein G, Klein E . Induction of tumor cell rejection in the low responsive YAC-lymphoma strain A host combination by immunization with somatic cell hybrids. Eur J Cancer (1965). 1979; 15(4):551-7. DOI: 10.1016/0014-2964(79)90092-6. View

Mihich E . Modification of tumor regression by immunologic means. Cancer Res. 1969; 29(12):2345-50. View

Romani L, Nardelli B, Bianchi R, Puccetti P, Mage M, Fioretti M . Adoptive immunotherapy of intracerebral murine lymphomas: role of different lymphoid populations. Int J Cancer. 1985; 35(5):659-65. DOI: 10.1002/ijc.2910350515. View

Rios A, Simmons R . Active specific immunotherapy of minimal residual tumor: excision plus neuraminidase-treated tumor cells. Int J Cancer. 1974; 13(1):71-81. DOI: 10.1002/ijc.2910130109. View

Bonmassar E, Bonmassar A, VADLAMUDI S, Goldin A . Antigenic changes of L1210 leukemia in mice treated with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide. Cancer Res. 1972; 32(7):1446-50. View

Koyama K, Ishii K . Induction of non-transplantable mutant clones from an ascites tumor. Gan. 1969; 60(4):367-72. View

Boon T, Van Snick J, Van Pel A, Uyttenhove C, Marchand M . Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis. J Exp Med. 1980; 152(5):1184-93. PMC: 2186002. DOI: 10.1084/jem.152.5.1184. View

Riccardi C, Fioretti M, Giampietri A, Puccetti P, Goldin A . Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo. Transplantation. 1978; 25(2):63-8. DOI: 10.1097/00007890-197802000-00005. View

10.

Benjamini E, Fong S, Erickson C, Leung C, Rennick D, Scibienski R . Immunity to lymphoid tumors in syngeneic mice by immunization with mitomycin C-treated cells. J Immunol. 1977; 118(2):685-93. View

11.

Nicolin A, VADLAMUDI S, Goldin A . Antigenicity of L1210 leukemic sublines induced by drugs. Cancer Res. 1972; 32(4):653-7. View

12.

Carlow D, Kerbel R, Feltis J, Elliott B . Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. J Natl Cancer Inst. 1985; 75(2):291-301. View

13.

Tsukagoshi S, Hashimoto Y . Increased immunosensitivity in nitrogen mastard-resistant Yoshida sarcoma. Cancer Res. 1973; 33(5):1038-42. View

14.

Boon T . Tum variants: immunogenic variants obtained by mutagen treatment of tumor cells. Immunol Today. 2014; 6(10):307-11. DOI: 10.1016/0167-5699(85)90182-3. View

15.

Georlette M, Boon T . Immunogenic cell variants of a mouse teratocarcinoma confer a protection against the original non-immunogenic transplantable tumor. Eur J Cancer Clin Oncol. 1981; 17(10):1083-7. DOI: 10.1016/0014-2964(81)90292-9. View

16.

Peppoloni S, Herberman R, Gorelik E . Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation. Cancer Res. 1985; 45(6):2560-6. View

17.

Boon T, Maryanski J . Tumour cell variants with increased immunogenicity obtained by mutagen treatment. Cancer Surv. 1985; 4(1):135-48. View

18.

CURRIE G, Bagshawe K . Tumour specific immunogenicity of methylcholanthrene-induced sarcoma cells after incubation in neuraminidase. Br J Cancer. 1969; 23(1):141-9. PMC: 2008319. DOI: 10.1038/bjc.1969.21. View

19.

Nardelli B, Puccetti P, Romani L, Sava G, Bonmassar E, Fioretti M . Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies. Cancer Immunol Immunother. 1984; 17(3):213-7. PMC: 11039226. DOI: 10.1007/BF00205488. View

20.

Kobayashi H . Viral xenogenization of intact tumor cells. Adv Cancer Res. 1979; 30:279-99. DOI: 10.1016/s0065-230x(08)60899-4. View